RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > In Focus: The Future of In Vitro Diagnostics

In Focus: The Future of In Vitro Diagnostics

Posted 01 May 2011 | By Robert Schiff, PhD, RAC, CQA, FRAPS

The May issue on in vitro diagnostics brings a variety of articles from very experienced authors in the regulatory area.According to the US Food and Drug Administration (FDA), "In vitro diagnostic products are those reagents, instruments, and systems intended for use in diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such products are intended for use in the collection, preparation, and examination of specimens taken from the human body." They are still medical devices and most are administered under the Center for Devices and Radiologic Health (CDRH). However, those involving the blood supply are reviewed by the Center for Biologics Evaluation and Research (CBER).

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.